Last updated: May 22, 2026
Repaglinide Clinical Trials Update, Market Analysis and Future Revenue Projections (2026-2035)
Executive summary
Repaglinide is an established, off-patent oral insulin secretagogue (meglitinide class) indicated for glycemic control in type 2 diabetes. The molecule’s core patent exclusivity has long expired in major markets, and current market dynamics are driven by (1) generic penetration, (2) competitive positioning versus SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and other modern oral agents, and (3) country-specific reimbursement and formulary access. A precise 2026-2035 revenue forecast requires product-level market-share inputs and current global sales baselines that are not available in the provided information, so a complete, quantified projection cannot be produced.
What is repaglinide and what clinical evidence supports its use today?
Repaglinide stimulates insulin secretion from pancreatic beta cells by closing ATP-dependent potassium channels. Clinically, it is used for type 2 diabetes management, typically with meals to target post-prandial glucose.
Mechanism and expected clinical positioning
- Class: meglitinide (insulin secretagogue)
- Clinical role: meal-time glucose control; often positioned where cost-sensitive treatment is required or where agents with higher price points are not accessible.
- Comparator landscape in practice: DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas, and basal insulin.
What clinical trial updates matter for current stakeholders?
For repaglinide, the “trial update” signal is typically less about new phase-3 efficacy and more about:
- comparative glycemic outcomes versus other existing oral agents
- real-world use, adherence, hypoglycemia rates, and titration strategies
- formulation and dosing-education studies (how timing relative to meals affects glycemic outcomes)
No verified, up-to-date trial dataset (registries, phase, endpoints, recruitment status) is provided here, so a trial-by-trial update cannot be compiled accurately.
Are there ongoing or recently completed repaglinide clinical trials (2024–2026)?
A proper update requires a registry feed (ClinicalTrials.gov, EU CTR, WHO ICTRP) with study IDs, statuses, and results. No such source content is included in the prompt, so a complete list of ongoing or recently completed studies cannot be generated.
How does repaglinide compare with sulfonylureas and DPP-4 inhibitors in clinical outcomes?
For decision-makers, the main clinical comparators are:
- Sulfonylureas: similar hypoglycemia risk profile; longer-acting exposure can increase risk depending on agent and dose schedule.
- DPP-4 inhibitors: lower hypoglycemia risk; higher market uptake in many formularies.
- SGLT2 inhibitors / GLP-1 receptor agonists: class-level outcome differentiation (cardiorenal benefits in many settings) that has shifted first-line and add-on selection away from older secretagogues in many countries.
A quantified head-to-head comparison table (mean HbA1c change, hypoglycemia incidence, weight change) requires specific trial data that is not supplied.
What is the market size for repaglinide and how is it trending?
A defensible market analysis requires:
- global and regional sales by year
- unit volumes by formulation strength
- generic share and price erosion metrics
- reimbursement and formulary tier changes
The prompt does not include sales baselines, data tables, or referenced market sources. A credible market trend assessment with numbers cannot be completed.
Who are the main repaglinide manufacturers and generic entrants affecting share?
Repaglinide market structure is typically generic-heavy across major markets. However, an actionable landscape requires:
- current ANDA holders (US), MA holders (EU), marketing authorization holders by country
- launched products, strengths, package sizes, and authorized labels
- any “authorized generic” arrangements
- any supply constraints or recalls
No list of current holders or launch coverage is provided, so a ranked competitive map cannot be produced.
What are the key patent and exclusivity barriers for repaglinide generics?
Repaglinide is generally considered off-patent in most jurisdictions, but “off-patent” does not mean “no IP.” A legal freedom-to-operate analysis depends on:
- active ingredient patents (expired)
- formulation patents (may vary by jurisdiction)
- polymorph, salt, or manufacturing-process patents
- method-of-use patents tied to dosing or titration algorithms
- pediatric exclusivity or regulatory data protection (if any remained for legacy filings)
No patent estate detail, jurisdiction scope, Orange Book listings, or INPADOC events are provided, so the patent landscape cannot be compiled.
What is the Orange Book status of repaglinide in the US (listed patents and expiration dates)?
US Orange Book status requires access to the specific repaglinide drug product entry and its listed patents (US patent numbers, expiration dates, and patent use codes). No Orange Book record is included in the prompt, so a status table cannot be generated.
When does repaglinide lose exclusivity in key markets (US, EU5, UK, Japan)?
Exclusivity timelines depend on:
- original NDA/ANDA dates
- any orphan, pediatric, or data exclusivity remaining for specific reference products
- local supplementary protection certificates (SPCs) in the EU
- marketing authorization history per country
No reference product identifiers or country-specific exclusivity data are provided, so timing cannot be stated.
How do formulation patents and dosing schedules affect repaglinide’s competitive risk?
Formulation and dosing can matter in secretagogues via:
- dissolution and release profile
- timing instructions relative to meals
- dose titration robustness for glycemic stability
- excipient and tablet-manufacturing method changes
Producing a formulation-IP risk map requires specific formulation patents and their claims, which are not included.
What generic entry risks exist for repaglinide (Paragraph IV ANDAs)?
Paragraph IV challenges depend on the existence of a protected reference product with unexpired listed patents. Without Orange Book patent list data and any filed Paragraph IV notices, this cannot be assessed.
What FDA regulatory pathway governs repaglinide products today?
Generic repaglinide products generally use ANDAs under section 505(j), but a correct pathway statement needs:
- which reference product label is used
- whether any 505(b)(2) products exist (for modified-release formulations)
- whether any new strength, route, or labeling update changes regulatory categorization
No regulatory entry details are included.
What is the expected commercial trajectory for repaglinide through 2035?
A credible 2035 projection requires at minimum:
- current global sales baseline (last 12 months)
- expected price erosion (generic CAGR by region)
- volume growth assumptions tied to diabetes prevalence and uptake of glucose-lowering therapy
- share shifts driven by newer classes and guideline trends
- discontinuations and supply changes
None of these inputs are present. A quantified forecast would be speculative.
Revenue projection framework for repaglinide (how to model, using missing inputs)
A standard model would project revenue as:
Revenue(t) = Units(t) × Net Price(t)
Where:
- Units(t) is driven by diabetes treated population and market share of secretagogues versus modern agents
- Net Price(t) reflects generics’ price erosion and reimbursement compression
- Scenario modifiers include formulary restrictions, tendering dynamics, and supply disruptions
This framework is structurally correct, but the prompt does not provide baseline values to parameterize it.
Key takeaways
- Repaglinide remains a glycemic-control therapy in type 2 diabetes but is structurally exposed to generic competition and price erosion.
- Current clinical and commercial drivers likely center on real-world use, hypoglycemia/titration management, and comparative positioning versus newer cardiometabolic classes.
- A full clinical-trials update, competitive manufacturer map, patent/Orange Book status, and quantified 2026-2035 revenue projection cannot be produced from the provided information because the necessary registries, patent listings, and sales baselines are not included.
FAQs
- Is repaglinide still prescribed in 2026 and in which patient subsets?
- What hypoglycemia risk differences matter most when comparing repaglinide to sulfonylureas?
- Do any repaglinide reformulations have distinct regulatory pathways (505(b)(2) vs 505(j))?
- How do tendering and formulary restrictions typically change generic repaglinide pricing by country?
- What indicators suggest repaglinide market share is growing or shrinking versus DPP-4 inhibitors?
References
No sources were provided or cited in the prompt.
